Core Viewpoint - The company has received approval for the production and sale of Moxifloxacin Hydrochloride Tablets, enhancing its product portfolio in the anti-infection sector [1][2]. Group 1: Product Approval - The company's wholly-owned subsidiary, Harbin Zhenbao Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Moxifloxacin Hydrochloride Tablets from the National Medical Products Administration [1]. - Moxifloxacin is a broad-spectrum antibacterial agent effective against various bacteria, including Gram-positive, Gram-negative, anaerobic, and atypical microorganisms [1]. Group 2: Market Impact - The approval allows the company to expand its core product offerings in the anti-infection field, thereby increasing its competitiveness in the systemic anti-infection market [2]. - The introduction of Moxifloxacin Hydrochloride Tablets will not have a significant impact on the company's current operating performance [2].

Core Viewpoint - The announcement by Zhenbao Island (603567) regarding the approval of moxifloxacin hydrochloride tablets by the National Medical Products Administration indicates a significant development in the company's pharmaceutical portfolio, potentially enhancing its market position in the antibacterial drug segment [1] Group 1: Company Developments - Zhenbao Island's wholly-owned subsidiary, Harbin Zhenbao Pharmaceutical Co., Ltd., has received the drug registration certificate for moxifloxacin hydrochloride tablets [1] - The company has invested approximately 13.64 million RMB in the research and development of this drug [1] Group 2: Market Context - Moxifloxacin hydrochloride is a broad-spectrum antibacterial agent used for treating various bacterial infections [1] - There are currently 24 approved manufacturers of moxifloxacin hydrochloride tablets in China, with a market size reaching 530 million RMB [1] - The production and sales of this drug are subject to significant uncertainties due to national policies and market environment changes [1]

附件 中药材GAP符合性延伸检查结果 | 被检查 | | 中药 | 基地建设 | 基地面积 | | | 本次检查 | 检 查 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 主体 | 被检查品种 | 材品 种 | 单位 | （亩） | 基地地址 | 经纬度坐标 | 预计产量 | 结 | | | | 黄芪 | 甘肃九州 | | 甘肃省定西市岷县 | 地理位置： | | 果 符 | | | | | 天润 中药产业 | | 申都乡青土村 | 点位1:东经104°31′457″， 北纬34°40′529″； | | 合 要 | | | | | 有限公司 | | | | | 求 | | 黑龙江珍宝岛药 | 黄芪注射液，10ml规格（国药准字 | | | | | 点位2:东经104°32′719″， | | | | 业股份有限公司 | Z23020782）；20ml规格（国药准字 | | | 2920亩 | | 北纬34°41′333″； | 150020kg | | | | Z23020862） | | | | | 点位3:东经104°32′839 ...

证券日报网讯12月1日，珍宝岛（603567）在互动平台回答投资者提问时表示，公司高度重视和关注公 司价值及股东利益，将持续聚焦主业，优化经营管理，积极探索更多的发展机会，同时通过增强信息披 露透明度、持续加强与各市场主体的沟通交流等方式积极开展市值管理工作，传递经营理念和投资价 值，更好地实现公司的长远发展和股东回报。关于股份回购或增持计划，公司将结合市场环境、资金状 况及监管要求统筹考量，如有具体计划将按规定及时披露。 ...

近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"或"珍宝岛"） 收到控股股东黑龙江创达集团有限公司（以下简称"创达集团"）的通知，创达 集团 2023 年面向专业投资者非公开发行可交换公司债券（第一期）（以下简称"第 一期可交债"）换股价格将进行调整，现将有关事项公告如下： 一、控股股东可交换公司债券的基本情况 公司控股股东创达集团已于 2023 年 4 月 11 日完成第一期可交债的发行。本 期可交债简称"23 创 01EB"，债券代码"137171"，发行规模 9.1 亿元，债券期 限 3 年。具体内容详见公司于 2023 年 4 月 12 日在上海证券交易所网站披露的临 2023-019 号公告。 二、控股股东可交换公司债券本次换股价格调整情况 证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-080 黑龙江珍宝岛药业股份有限公司 关于控股股东非公开发行可交换公司债券 换股价格调整的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 黑龙江珍宝岛药业股份有限公司董事会 2025 年 11 月 ...

Group 1 - The Chinese medicine sector experienced a decline of 0.83% on November 28, with Yue Wannianqing leading the drop [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] - Key stocks in the Chinese medicine sector showed mixed performance, with Tai Long Pharmaceutical rising by 5.37% to a closing price of 8.04 [1] Group 2 - Yue Wannianqing saw a significant drop of 13.71%, closing at 22.84, with a trading volume of 296,100 shares [2] - Other notable declines included Zhongsheng Pharmaceutical, which fell by 10.00% to 23.95, and Te Yi Pharmaceutical, which decreased by 6.41% to 14.01 [2] - The overall net capital flow in the Chinese medicine sector indicated a net outflow of 981 million yuan from main funds, while retail investors contributed a net inflow of 766 million yuan [2]

Group 1 - The company will hold its third extraordinary general meeting of shareholders on December 11, 2025, at 14:00 in Harbin [2][5][11] - The voting method for the meeting will combine on-site voting and online voting through the Shanghai Stock Exchange's network voting system [3][5] - The online voting will be available on the same day from 9:15 to 15:00, with specific time slots for trading system voting [3][7] Group 2 - The board of directors has approved the proposal to renew the appointment of the auditing firm Zhongshui Yatai for the 2025 fiscal year, with a fee of RMB 1.5 million [21][25] - The auditing firm has a history of providing services since its establishment in 1993 and has a significant number of registered accountants [26][27] - The proposal for the renewal of the auditing firm will also be submitted for approval at the upcoming extraordinary general meeting [34][35]

Core Viewpoint - The company, Zhenbaodao, announced its board meeting to discuss the reappointment of the auditing firm for the fiscal year 2025, indicating ongoing governance and compliance efforts [1] Financial Performance - For the fiscal year 2024, Zhenbaodao's revenue composition is as follows: pharmaceutical manufacturing accounts for 87.78%, pharmaceutical distribution for 11.13%, and other businesses for 1.09% [1] - The current market capitalization of Zhenbaodao is 9.7 billion yuan [1] Regulatory Issues - Another company, identified as 688496, is under investigation by the China Securities Regulatory Commission (CSRC) due to a significant loss exceeding 100 million yuan shortly after its IPO, with its main customer reducing purchases [1]

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-078 黑龙江珍宝岛药业股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （6）人员信息： ●拟续聘的会计师事务所名称：中审亚太会计师事务所（特殊普通合伙）（以 下简称"中审亚太"） 公司于 2025 年 11 月 24 日召开的第五届董事会第二十八次会议审议并通过 了《关于续聘公司 2025 年度审计机构的议案》，拟续聘中审亚太为公司 2025 年度财务报告及内部控制审计机构，本事项尚需提交公司 2025 年第三次临时股 东会审议。现将相关事项公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 （1）机构名称：中审亚太会计师事务所（特殊普通合伙） （2）成立日期：1993 年 3 月 2 日（中审亚太会计师事务所（特殊普通合伙） 前身为中国审计事务所，后经合并改制于 2013 年 1 月 18 日变更为中审亚太会计 师事务所（特殊普通合伙））。 （3）组织形式：特殊普通合伙 （4） ...

(一) 股东会类型和届次 2025年第三次临时股东会 证券代码：603567 证券简称：珍宝岛 公告编号：临2025-079 黑龙江珍宝岛药业股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 11 日 至2025 年 12 月 11 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所上市 ...